JAGSONPAL PHARMACEUTICALS Latest Share Price (JAGSNPHARM)
TODAY IN ONE LINE
JAGSNPHARM is little changed at ₹232.89 on light volume — a quiet consolidation day.
With a market cap of ₹1,537.26 Cr., it trades at a P/E of 34.02. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
JAGSONPAL PHARMACEUTICALS flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 23.8% YoY
- ●High Capital EfficiencyROCE of 16.5% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 15.6%
- ●Healthy Operating MarginsOPM is structurally strong at 20.4%
- ●High Promoter HoldingPromoters hold 68.7% skin-in-the-game
- ●Steady Dividend YieldReliable 2.78% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 71.4% YoY
- ●Promoter SellingPromoter holding decreased by 17.22% QoQ
Latest JAGSONPAL PHARMACEUTICALS News
What changed recently?
Recent events, corporate actions, and announcements.
JAGSONPAL PHARMACEUTICALS valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for JAGSONPAL PHARMACEUTICALS, framed against the sector median so the premium or discount is obvious at a glance.
JAGSONPAL PHARMACEUTICALS trades at a P/E of 34.02× and P/B of 5.64×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
JAGSONPAL PHARMACEUTICALS technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for JAGSONPAL PHARMACEUTICALS — derived from the latest tape, not yesterday's close.
JAGSONPAL PHARMACEUTICALS last traded at ₹232.89 with an intraday range of ₹228.01–₹234.6 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹232.89| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 248.84 | +15.95 | +6.85% |
| R3 | 242.25 | +9.36 | +4.02% |
| R2 | 238.42 | +5.53 | +2.38% |
| R1 | 235.66 | +2.77 | +1.19% |
| PIVOT | 231.83 | -1.06 | -0.45% |
| CURRENT | 232.89 | — | — |
| S1 | 229.07 | -3.82 | -1.64% |
| S2 | 225.24 | -7.65 | -3.28% |
| S3 | 222.48 | -10.41 | -4.47% |
| S4 | 215.89 | -17.00 | -7.30% |
JAGSNPHARM is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹228.01–₹232.79
Trading Inside opening range
JAGSONPAL PHARMACEUTICALS financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for JAGSONPAL PHARMACEUTICALS — consolidated or standalone — with margins, YoY growth and key ratios inline.
JAGSONPAL PHARMACEUTICALS reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,537.26 Cr. and reported EPS of ₹2.00.
JAGSONPAL PHARMACEUTICALS segment analysis : revenue and profit mix.
Disclosed business segments at JAGSONPAL PHARMACEUTICALS with their share of revenue and profit, switchable between consolidated and standalone reporting.
JAGSONPAL PHARMACEUTICALS discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for JAGSONPAL PHARMACEUTICALS.
Our AI distills the core fundamental drivers supporting JAGSONPAL PHARMACEUTICALS, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
JAGSONPAL PHARMACEUTICALS's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 44 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 11% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 1.39%.
JAGSONPAL PHARMACEUTICALS peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — JAGSONPAL PHARMACEUTICALS is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
JAGSONPAL PHARMACEUTICALS chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for JAGSONPAL PHARMACEUTICALS — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
JAGSONPAL PHARMACEUTICALS delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for JAGSONPAL PHARMACEUTICALS over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in JAGSONPAL PHARMACEUTICALS stood at 52.2% of traded volume, against a 20-day average of 50.4%.
JAGSONPAL PHARMACEUTICALS announcements: results, concalls, ratings, M&A.
Filings JAGSONPAL PHARMACEUTICALS sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
JAGSONPAL PHARMACEUTICALS files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 120 documents below.
Copy of Newspaper Publication
Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Shareholders meeting
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 18, 2026
Updates
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'providing a web-link of the Annual Report 2025-26 to members'.
Updates
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited…
Copy of Newspaper Publication
Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication on 47th Annual General Meeting (AGM) of the Company…
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
JAGSONPAL PHARMACEUTICALS dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue JAGSONPAL PHARMACEUTICALS has declared, sequenced by announce and record date.
JAGSONPAL PHARMACEUTICALS corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About JAGSONPAL PHARMACEUTICALS: business, sector, key facts.
What JAGSONPAL PHARMACEUTICALS does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
JAGSONPAL PHARMACEUTICALS operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: JAGSNPHARM, BSE: 507789.
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) is a pharmaceutical company primarily operating in India but also with an international presence. Their core business revolves around the manufacturing, sale, and trading of pharmaceutical products and active pharmaceutical ingredients (APIs).
The company's product portfolio spans a variety of therapeutic areas, with a notable focus on gynecology, orthopedics, dermatology, and pediatrics. This specialization allows them to cater to a diverse range of patient needs and healthcare requirements.
JAGSNPHARM offers its products in multiple dosage forms, including tablets, softgels, injections, capsules, and syrups. This diverse range of delivery methods enables flexibility in addressing various patient preferences and treatment requirements. The variety of forms also suggests a broad range of active ingredients and formulations within their product lines.
Their customer base includes both healthcare professionals, such as doctors and pharmacists, and government institutions. This dual market approach signifies a robust and diversified distribution network, lessening dependence on any single customer segment. The inclusion of government institutions suggests a presence in public health initiatives and contracts.
Established in 1978 and headquartered in New Delhi, India, JAGSNPHARM benefits from a long operational history in the Indian pharmaceutical market. This longevity suggests established supply chains, manufacturing capabilities, and regulatory compliance.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about JAGSONPAL PHARMACEUTICALS (JAGSNPHARM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of JAGSONPAL PHARMACEUTICALS (JAGSNPHARM)?
The current share price of JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) is ₹232.89. Today, the stock has declined by ₹0.10 (0.04%), trading in a range of ₹228.01 to ₹234.60. The stock opened at ₹229.21 with a trading volume of 51,421 shares.
02Is JAGSONPAL PHARMACEUTICALS stock a good investment for long-term?
JAGSONPAL PHARMACEUTICALS can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,537.26 Cr., P/E ratio of 34.02, ROE of 15.6%, and ROCE of 16.48%. The dividend yield stands at 2.78%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of JAGSONPAL PHARMACEUTICALS stock?
The 52-week high price of JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) is ₹264.50, while the 52-week low is ₹155.00. Currently trading at ₹232.89, the stock is 50.25% above its 52-week low and 11.95% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy JAGSONPAL PHARMACEUTICALS stock at the current price?
Whether to buy JAGSONPAL PHARMACEUTICALS stock at ₹232.89 depends on multiple factors. The stock is currently trading with a P/E ratio of 34.02 and P/B ratio of 5.64. Today's performance shows a loss of 0.04%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of JAGSONPAL PHARMACEUTICALS and when is the next dividend?
JAGSONPAL PHARMACEUTICALS offers a dividend yield of 2.78%, which means for every ₹100 invested at the current price of ₹232.89, you can expect to receive approximately ₹2.78 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of JAGSONPAL PHARMACEUTICALS?
JAGSONPAL PHARMACEUTICALS's key financial metrics include: P/E Ratio: 34.02, P/B Ratio: 5.64, ROE: 15.6%, ROCE: 16.48%, Dividend Yield: 2.78%, EPS: ₹2.00, Book Value: ₹41.95, and Debt-to-Equity: 0. The company's market cap stands at ₹1,537.26 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is JAGSONPAL PHARMACEUTICALS stock performing today in the market?
JAGSONPAL PHARMACEUTICALS stock opened at ₹229.21 and is currently trading at ₹232.89, showing a decline of ₹0.10 (0.04%). The intraday high is ₹234.60 and low is ₹228.01. The trading volume stands at 51,421 shares, indicating moderate market participation today.
08What is the P/E ratio of JAGSONPAL PHARMACEUTICALS and what does it indicate?
JAGSONPAL PHARMACEUTICALS has a Price-to-Earnings (P/E) ratio of 34.02, which means investors are willing to pay 34.02 for every ₹1 of earnings. With an EPS of ₹2.00, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.